
#CRCTrialsChat
@crctrialschat
Let's learn about CRC #Clinicaltrials
Patients, caregivers, clinicians, patient advocates: All are welcome!
Volunteer activity organized by @manjuggm
ID: 1525527871430729728
https://wakelet.com/@CRCTrialsChat257 14-05-2022 17:26:38
4,4K Tweet
961 Followers
1,1K Following

.Manju George MVSc PhD Rectal Cancer Survivor highlights the value and community of Colontown to patients with CRC and caregivers. Love seeing this group get praise. #GI24



Dr. Rakesh K. Jain honored with #AACR25 Lifetime Achievement in #CancerResearch for his pioneering contributions to understanding the TME. He shares that his first R01 was rejected 6 times. A great lesson in passion + persistence! Harvard University MassGeneral News AACR





Dr Margaret Foti, PhD, MD (hc) presents Tammy Baldwin the #AACR25 Distinguished Public Service Award for her leadership in addressing the growing threats and consequences on patients, researchers, clinicians. Thank YOU Senator Baldwin!


I think so for colorectal and esophageal, considering also SANO trial, increasingly the question is can we hold off on surgery or reserve for salvage and that answer building “yes” evidence Dr. Nina Niu Sanford

Remote assessment of patients on clinical trial, via telemedicine, opens the door to more widespread enrollment from patients in rural areas and more. APOLLO trial in pancreatic cancer is the first NCI-funded trial to allow this -Shaalan Beg MD MBA FASCO #AACR25 Plenary



Early-onset colorectal cancer clinical challenges. A great talk by Cassandra Fritz, MD, MPHS at #AACR2025! #AACR25 #EOCRC





#ASCO25 is less than 4 weeks away! Honored to be among ASCO’s “Featured Voices,” representing general medical oncologists and our community. Follow these featured voices 👇👇 to stay updated on the latest in oncology!! #OncTwitter #MedTwitter #MedEd Roswell Park Wilmot Cancer Institute


👀Adjuvant aspirin 160 mg for 3 years- now in NCCN for patients with PIK3CA mutated #ColorectalCancer 👉ALASCCA trial showed ⬇️ 3-year recurrence. 👉Results even more impressive in patients with PIK3R1 and PTEN mutant cancers (+DFS benefit) ❓How are oncologists obtaining this

Congrats to Michael LaPelusa, MD for a great study adding to the avalanche of data showing neoadjuvant PDL1 for MSI-H rectal cancer is safe and effective! 3 year followup for pembrolizumab in MSI-H localized rectal cancer Strong use-case for ctDNA monitoring 3-year EFS 92% vs

It's been a month since we moved to MS! I started as an Asst Professor in the Dept of Population Science at the John D Bower School of Pop Health. Also working with UMMC Cancer Center and Research Institute to chair the MS #colorectalcancer Roundtable. To improving #CRC outcomes in MS! Rod Rocconi #CRCSM
